ID
16696
Descripción
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of Study: Adverse Events
Link
https://clinicaltrials.gov/ct2/show/NCT00373425
Palabras clave
Versiones (1)
- 1/8/16 1/8/16 -
Subido en
1 de agosto de 2016
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Adverse Events, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425
Adverse Events, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
Descripción
Long-Term Follow-Up Adverse Events
Descripción
Record ALL Baseline Signs and Symptoms that occur within 24 hours prior to First Dosing. ALL Adverse Events, including Serious Adverse Events should be recorded. In addition, ALL Serious Adverse Events must be recorded on the Serious Adverse Event Report Form.
Tipo de datos
text
Alias
- UMLS CUI [1]
- C0877248
Descripción
Grade severity (1,2,3,4,5) using NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0. A change in CTC grade should be recorded as a separate event.
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C1710066
Descripción
Adverse Event Start Date
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C2697888
Descripción
If not pretreatment, please specify start date
Tipo de datos
date
Alias
- UMLS CUI [1]
- C2697888
Descripción
Adverse Event End Date
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C2697886
Descripción
If not continuing, please specify stop date
Tipo de datos
date
Alias
- UMLS CUI [1]
- C2697886
Descripción
If event is serious, complete the SERIOUS ADVERSE EVENT FORM and fax to the appropriate number on the CRF General lnstructions page.
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C1710056
Descripción
A change in relationship should be recorded as a separate event.
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C1510821
Descripción
If event caused drug discontinuation, complete the Withdrawal From Study Due To Nonserious Adverse Event Form and fax to the appropriate number on the CRF General lnstructions page.
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C2826626